Nuvation Bio/NUVB

$3.28

-0.61%
-
1D1W1MYTD1YMAX

About Nuvation Bio

Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.

Ticker

NUVB

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

David Hung

Employees

159

Headquarters

San francisco, United States

Nuvation Bio Metrics

BasicAdvanced
$814M
Market cap
-
P/E ratio
-$0.35
EPS
1.44
Beta
-
Dividend rate
$814M
1.44078
$4.16
$0.95
1.5M
44.113
-11.72%
-12.03%
-11.97%
1.195
1.345
27.95%

What the Analysts think about Nuvation Bio

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 5 analysts.
79.88% upside
High $10.00
Low $4.50
$3.28
Current price
$5.90
Average price target

Nuvation Bio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$15M
7.3%
Profit margin
0%
NaN%

Nuvation Bio Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 26.93%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.09
-$0.09
-$0.06
-$0.07
-
Expected
-$0.11
-$0.11
-$0.10
-$0.10
-$0.07
Surprise
-19.52%
-17.93%
-42.77%
-26.93%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Nuvation Bio stock?

Nuvation Bio (NUVB) has a market cap of $821M as of May 20, 2024.

What is the P/E ratio for Nuvation Bio stock?

The price to earnings (P/E) ratio for Nuvation Bio (NUVB) stock is 0 as of May 20, 2024.

Does Nuvation Bio stock pay dividends?

No, Nuvation Bio (NUVB) stock does not pay dividends to its shareholders as of May 20, 2024.

When is the next Nuvation Bio dividend payment date?

Nuvation Bio (NUVB) stock does not pay dividends to its shareholders.

What is the beta indicator for Nuvation Bio?

Nuvation Bio (NUVB) has a beta rating of 1.44. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Nuvation Bio stock price target?

The target price for Nuvation Bio (NUVB) stock is $5.9, which is 77.71% above the current price of $3.32. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Nuvation Bio stock

Buy or sell Nuvation Bio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing